U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Metastatic Lung Non-Small Cell Squamous Carcinoma

MedGen UID:
1679728
•Concept ID:
C4763570
•
Neoplastic Process
Synonyms: Metastatic Non-Small Cell Squamous Lung Carcinoma; Metastatic Squamous Non-Small Cell Lung Carcinoma

Definition

A squamous non-small cell carcinoma that arises from the lung and has metastasized to another anatomic site. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMetastatic Lung Non-Small Cell Squamous Carcinoma

Professional guidelines

PubMed

Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A, Ramlau R, Stencel K
Int J Mol Sci 2021 Jan 8;22(2) doi: 10.3390/ijms22020593. PMID: 33435596Free PMC Article
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE
Am Fam Physician 2007 Jan 1;75(1):56-63. PMID: 17225705

Recent clinical studies

Etiology

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
J Thorac Oncol 2023 Jun;18(6):755-768. Epub 2023 Mar 29 doi: 10.1016/j.jtho.2023.03.008. PMID: 37001859
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS
JAMA Oncol 2021 Sep 1;7(9):1368-1377. doi: 10.1001/jamaoncol.2021.2209. PMID: 34264316Free PMC Article
CCDC85B promotes non-small cell lung cancer cell proliferation and invasion.
Feng Y, Gao Y, Yu J, Jiang G, Zhang X, Lin X, Han Q, Rong X, Xu H, Li Q, Qiu X, Wang E
Mol Carcinog 2019 Jan;58(1):126-134. Epub 2018 Oct 9 doi: 10.1002/mc.22914. PMID: 30242906
Innovative Clinical Trials: The LUNG-MAP Study.
Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, Ramalingam SS, Gandara DR
Clin Pharmacol Ther 2015 May;97(5):488-91. doi: 10.1002/cpt.88. PMID: 25676724
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Diagnosis

Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway.
Chen B, Song Y, Zhan Y, Zhou S, Ke J, Ao W, Zhang Y, Liang Q, He M, Li S, Xie F, Huang H, Chan WN, Cheung AHK, Ma BBY, Kang W, To KF, Xiao J
Cancer Lett 2022 Sep 1;543:215783. Epub 2022 Jun 11 doi: 10.1016/j.canlet.2022.215783. PMID: 35700820
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B
JAMA Oncol 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771. PMID: 29327044Free PMC Article
Progress and prospects of early detection in lung cancer.
Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T, Dive C
Open Biol 2017 Sep;7(9) doi: 10.1098/rsob.170070. PMID: 28878044Free PMC Article
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article
Lung cancer: diagnosis and management.
Collins LG, Haines C, Perkel R, Enck RE
Am Fam Physician 2007 Jan 1;75(1):56-63. PMID: 17225705

Therapy

Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee KH, Golf A, Sugawara S, Robinson AG, Halmos B, Jensen E, Schwarzenberger P, Pietanza MC, Paz-Ares L
J Clin Oncol 2023 Apr 10;41(11):1999-2006. Epub 2023 Feb 3 doi: 10.1200/JCO.22.01990. PMID: 36735893Free PMC Article
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.
Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, Hermes B, Cicin I, Medgyasszay B, Rodríguez-Cid J, Okamoto I, Lee S, Ramlau R, Vladimirov V, Cheng Y, Deng X, Zhang Y, Bas T, Piperdi B, Halmos B
J Thorac Oncol 2020 Oct;15(10):1657-1669. Epub 2020 Jun 26 doi: 10.1016/j.jtho.2020.06.015. PMID: 32599071
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA
Mayo Clin Proc 2008 May;83(5):584-94. doi: 10.4065/83.5.584. PMID: 18452692Free PMC Article

Prognosis

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li S, Li Y, Kaul M, Quek RGW, Pouliot JF, Seebach F, Lowy I, Gullo G, Rietschel P
J Thorac Oncol 2023 Jun;18(6):755-768. Epub 2023 Mar 29 doi: 10.1016/j.jtho.2023.03.008. PMID: 37001859
CCDC85B promotes non-small cell lung cancer cell proliferation and invasion.
Feng Y, Gao Y, Yu J, Jiang G, Zhang X, Lin X, Han Q, Rong X, Xu H, Li Q, Qiu X, Wang E
Mol Carcinog 2019 Jan;58(1):126-134. Epub 2018 Oct 9 doi: 10.1002/mc.22914. PMID: 30242906
Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.
Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, Wen PY, Dunn IF, Bi WL, Weiss SE, Haas-Kogan DA, Alexander BM, Aizer AA
Neuro Oncol 2017 Oct 19;19(11):1511-1521. doi: 10.1093/neuonc/nox077. PMID: 28444227Free PMC Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H
Lancet Oncol 2015 Feb;16(2):187-99. Epub 2015 Jan 16 doi: 10.1016/S1470-2045(14)71207-0. PMID: 25601342Free PMC Article

Clinical prediction guides

Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Shi Y, Wu L, Yu X, Xing P, Wang Y, Zhou J, Wang A, Shi J, Hu Y, Wang Z, An G, Fang Y, Sun S, Zhou C, Wang C, Ye F, Li X, Wang J, Wang M, Liu Y, Zhao Y, Yuan Y, Feng J, Chen Z, Shi J, Sun T, Wu G, Shu Y, Guo Q, Zhang Y, Song Y, Zhang S, Chen Y, Li W, Niu H, Hu W, Wang L, Huang J, Zhang Y, Cheng Y, Wu Z, Peng B, Sun J, Mancao C, Wang Y, Sun L
Cancer Commun (Lond) 2022 Dec;42(12):1314-1330. Epub 2022 Nov 6 doi: 10.1002/cac2.12385. PMID: 36336841Free PMC Article
Metastatic lung carcinoma in thyroid aspirates: A case series and literature review illustrating diagnostic challenges.
Ng JKM, Li JJX
Cytopathology 2022 Nov;33(6):696-706. Epub 2022 Jul 26 doi: 10.1111/cyt.13164. PMID: 35808980
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS
JAMA Oncol 2021 Sep 1;7(9):1368-1377. doi: 10.1001/jamaoncol.2021.2209. PMID: 34264316Free PMC Article
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D, Besse B, Groen HJM, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE
Lancet Oncol 2016 Jul;17(7):984-993. Epub 2016 Jun 6 doi: 10.1016/S1470-2045(16)30146-2. PMID: 27283860Free PMC Article
Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E, Genova C, Barletta G, Biello F, Dal Bello MG, Coco S, Truini A, Vanni I, Alama A, Boccardo F, Grossi F
Expert Opin Pharmacother 2014 Aug;15(12):1771-80. doi: 10.1517/14656566.2014.938639. PMID: 25032887

Recent systematic reviews

Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review.
Hall H, Tocock A, Burdett S, Fisher D, Ricketts WM, Robson J, Round T, Gorolay S, MacArthur E, Chung D, Janes SM, Peake MD, Navani N
Thorax 2022 Aug;77(8):762-768. Epub 2021 Aug 17 doi: 10.1136/thoraxjnl-2021-216865. PMID: 34404753Free PMC Article
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J, Boland A, Bates V, Vecchio F, Dundar Y, Chaplin M, Green JA
Cochrane Database Syst Rev 2021 Mar 18;3(3):CD010383. doi: 10.1002/14651858.CD010383.pub3. PMID: 33734432Free PMC Article
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Liu J, Li C, Seery S, Yu J, Meng X
Oncoimmunology 2020;9(1):1746112. Epub 2020 Apr 7 doi: 10.1080/2162402X.2020.1746112. PMID: 32313723Free PMC Article
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S
Lung Cancer 2019 Aug;134:127-140. Epub 2019 May 30 doi: 10.1016/j.lungcan.2019.05.029. PMID: 31319971
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J
Lung Cancer 2017 Oct;112:200-215. Epub 2017 Aug 10 doi: 10.1016/j.lungcan.2017.08.005. PMID: 29191596

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...